ECP effects on antigen presentation function of DCs
| Patient . | Organs involved . | Drugs at start of ECP . | Drugs at end of trial . | Onset of ECP from transplantation, d . | Months of ECP . | Response . | MLR . |
|---|---|---|---|---|---|---|---|
| 1 | Skin, joints, mouth | Prednisone, 20 mg/d FK506, 2 mg/d Tacrolimus, 2 mg/d | Prednisone, 10 mg/d | 600 | 9 | PR | Autologous |
| 2 | Skin, joints, mouth | Prednisone, 6 mg/d Tacrolimus, 1 mg/d | Prednisone, 3.5 mg/d Cellcept, 1000 bid Tacrolimus, DIC | 2928 | 9 | PR | Autologous |
| 3 | Skin, mouth | Prednisone, 25 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 12.5 mg/d CSA, 150 mg/d | 101 | 11 | PR | Autologous |
| 4 | Skin, joints, mouth, liver | Prednisone, 20 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 10 mg/d CSA, 50 mg/d | 204 | 10 | PR | Allogeneic |
| 5 | Skin, lungs | Prednisone, 20 mg/d | Prednisone, 20 mg/d | 122 | 4 | NC* | Allogeneic |
| 6 | Skin, lungs | Prednisone, 22.5 mg/d Cellcept, 500 mg bid | Prednisone, 17.5 mg/d | 221 | 9 | PR skin improved, lungs unchanged | Allogeneic |
| 7 | Skin, eye, liver | Prednisone, 20 mg/d Plaquenil, 200 mg/d | Prednisone, 10 mg/d Plaquenil, DIC | 457 | 4 | PR | Autologous |
| 8 | Skin, joints, mouth | Prednisone, 10 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 10 mg/d MMF, 1.5 g/d | 496 | 16 | PR | Autologous |
| 9 | Skin, mouth | Prednisone, 20 mg QOD Cellcept, 1000 mg/d | Cellcept, 500 bid | 1342 | 9 | PR skin improved | Autologous |
| 10 | Skin, joints, mouth | Prednisone, 10 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 10 mg/d CSA, 50 mg/d | 189 | 12 | NC | Autologous |
| Patient . | Organs involved . | Drugs at start of ECP . | Drugs at end of trial . | Onset of ECP from transplantation, d . | Months of ECP . | Response . | MLR . |
|---|---|---|---|---|---|---|---|
| 1 | Skin, joints, mouth | Prednisone, 20 mg/d FK506, 2 mg/d Tacrolimus, 2 mg/d | Prednisone, 10 mg/d | 600 | 9 | PR | Autologous |
| 2 | Skin, joints, mouth | Prednisone, 6 mg/d Tacrolimus, 1 mg/d | Prednisone, 3.5 mg/d Cellcept, 1000 bid Tacrolimus, DIC | 2928 | 9 | PR | Autologous |
| 3 | Skin, mouth | Prednisone, 25 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 12.5 mg/d CSA, 150 mg/d | 101 | 11 | PR | Autologous |
| 4 | Skin, joints, mouth, liver | Prednisone, 20 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 10 mg/d CSA, 50 mg/d | 204 | 10 | PR | Allogeneic |
| 5 | Skin, lungs | Prednisone, 20 mg/d | Prednisone, 20 mg/d | 122 | 4 | NC* | Allogeneic |
| 6 | Skin, lungs | Prednisone, 22.5 mg/d Cellcept, 500 mg bid | Prednisone, 17.5 mg/d | 221 | 9 | PR skin improved, lungs unchanged | Allogeneic |
| 7 | Skin, eye, liver | Prednisone, 20 mg/d Plaquenil, 200 mg/d | Prednisone, 10 mg/d Plaquenil, DIC | 457 | 4 | PR | Autologous |
| 8 | Skin, joints, mouth | Prednisone, 10 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 10 mg/d MMF, 1.5 g/d | 496 | 16 | PR | Autologous |
| 9 | Skin, mouth | Prednisone, 20 mg QOD Cellcept, 1000 mg/d | Cellcept, 500 bid | 1342 | 9 | PR skin improved | Autologous |
| 10 | Skin, joints, mouth | Prednisone, 10 mg/d MMF, 2 g/d CSA, 200 mg/d | Prednisone, 10 mg/d CSA, 50 mg/d | 189 | 12 | NC | Autologous |
MLR data refer to maximal proliferation (pre– vs post–8-MOP/UVA exposure in cycle 3 of therapy; autologous vs allogeneic lymphocytes).
CSA indicates cyclosporin A.
DLI for recurrent lymphoma after third cycle of ECP.